S. Chow

Improvement in eGFR in patients with chronic kidney disease attending a nephrology clinic

H. Taskapan, D. Oreopoulos, T. Sikaneta, 2008, International Urology and Nephrology.

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

A. Villaflor, M. Pfeffer, C. Held, 2021, European heart journal.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

P. Gosse, S. Oparil, Pankaj Gupta, 2022, The Lancet.

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.

R. Janssen, D. Shemin, M. Girndt, 2023, Vaccine.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.